Please login to the form below

Not currently logged in


This page shows the latest ABT-450 news and features for those working in and with pharma, biotech and healthcare.

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen. The US FDA has granted priority review to AbbVie's all-oral regimen for the treatment of adult patients ... The regimen consists of the protease inhibitor ABT-450 boosted by

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain contenders for market share, scoring higher than J&J’s simeprevir in terms of likelihood to prescribe amongst doctors

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...